Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

Rhea-AI Summary

Xtant Medical Holdings, Inc. (NYSE American: XTNT) has launched OsteoVive Plus, a new moldable, viable bone matrix for various grafting procedures. This product expands Xtant's portfolio and is now available to their nationwide distribution network. OsteoVive Plus features Advanced Purloc™ Fiber Technology, offering a high concentration of elongated cortical fibers for optimal surgical placement.

The launch aligns with Xtant's strategy to drive margin improvement and generate positive operating cash flow. Manufactured at their Belgrade facility, OsteoVive Plus reinforces Xtant's position as an innovative medical technology company. The product will be showcased at the North American Spine Society (NASS) 2024 annual meeting from September 25-28 in Chicago.

Positive

• Launch of new product OsteoVive Plus, expanding market opportunities
• Product manufactured in-house at Belgrade facility, potentially improving margins
• Aligns with strategy to drive margin improvement and generate positive operating cash flow
• Reinforces company's position as an innovative medical technology company
• Product available through nationwide distribution network and OEM relationships

Negative

• None.

Medical Research Analyst

Xtant Medical's launch of OsteoVive Plus, a new viable bone matrix, represents a significant advancement in cellular bone technology. The product's Advanced Purloc™ Fiber Technology offers a high concentration of elongated cortical fibers, potentially improving surgical outcomes in grafting procedures. This innovation could give Xtant a competitive edge in the $2.9 billion global bone graft substitutes market. However, the true impact will depend on clinical performance and adoption rates among surgeons. The in-house manufacturing at their Belgrade facility may improve profit margins, but this needs to be balanced against development and production costs. While promising, we need to see real-world data and sales figures to fully assess its market potential.

Financial Analyst

The launch of OsteoVive Plus aligns with Xtant Medical's strategy to drive margin improvement and generate positive operating cash flow. In-house manufacturing at their Belgrade facility could potentially lead to better cost control and higher profit margins. However, the financial impact remains uncertain without specific revenue projections or pricing information. The expanded product portfolio may open new market opportunities, potentially increasing the company's market share in the spinal disorder treatment sector. Investors should monitor upcoming quarterly reports for early indications of OsteoVive Plus's contribution to revenue growth and margin expansion. The product's success could be a catalyst for Xtant's stock performance, but it's important to see concrete financial results before drawing definitive conclusions.

Market Research Analyst

The launch of OsteoVive Plus could strengthen Xtant Medical's position in the competitive bone graft substitutes market. The product's moldable and cohesive properties address surgeons' needs for ease of use and precise placement. Distribution through a nationwide network of independent agents and OEM relationships may facilitate rapid market penetration. However, success will depend on factors such as pricing strategy, reimbursement policies and the product's performance compared to existing alternatives. The upcoming NASS annual meeting provides a important platform for showcasing OsteoVive Plus to key stakeholders. Market reception at this event could be an early indicator of the product's potential. While the launch is promising, it's essential to monitor adoption rates and gather feedback from early users to gauge long-term market impact.

New Cellular Bone Matrix Designed with Cohesive and Moldable Handling Characteristics

BELGRADE, MT / ACCESSWIRE / September 18, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive Plus, a moldable, viable bone matrix that can be used in a variety of grafting procedures. The graft is now available, to the company's nationwide distribution network of independent agents as well as original equipment manufacturer relationships.

OsteoVive Plus

Sean Browne, President and CEO of Xtant Medical, stated, "New product launches are a key component of our strategy to drive margin improvement on higher sales and generate positive operating cash flow. OsteoVive Plus, which is manufactured in our Belgrade facility, expands our market opportunities and reinforces our position as an innovative medical technology company."

Mark Schallenberger, COO of Xtant Medical added, "OsteoVive Plus represents the latest advancement in cellular bone technology. Our new viable bone matrix features our Advanced Purloc™ Fiber Technology which includes a high concentration of elongated cortical fibers with consistent cross-sectional geometry, creating a moldable and cohesive allograft for optimal surgical placement."

OsteoVive Plus is manufactured at Xtant's state-of-the-art center for biologics processing in Belgrade, Montana.

The company will attend and showcase OsteoVive Plus along with its other products at the North American Spine Society (NASS) 2024 annual meeting.The conference is being held September 25-28, 2024 at McCormack Place in Chicago. Visit booth #4402 in the Exhibit Hall to learn more about Xtant and its product portfolio.

For additional information about OsteoVive Plus, please visit https://xtantmedical.com/product/osteovive-plus/ or contact sales support at cs@xtantmedical.com or (888) 886-9354.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "continue," "future," "will," "potential," "going forward," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the private placement, the timing for closing and the anticipated gross proceeds and use of net proceeds from the private placement. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainties surrounding the private placement; the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 1, 2024 and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331

SOURCE: Xtant Medical Holdings, Inc.

View the original press release on accesswire.com

FAQ

What is OsteoVive Plus and when did Xtant Medical (XTNT) launch it?

OsteoVive Plus is a moldable, viable bone matrix for grafting procedures, launched by Xtant Medical (XTNT) on September 18, 2024. It features Advanced Purloc™ Fiber Technology for optimal surgical placement.

How does OsteoVive Plus align with Xtant Medical's (XTNT) business strategy?

OsteoVive Plus aligns with Xtant Medical's strategy to drive margin improvement on higher sales and generate positive operating cash flow. It expands their market opportunities and reinforces their position as an innovative medical technology company.

Where is OsteoVive Plus manufactured by Xtant Medical (XTNT)?

OsteoVive Plus is manufactured at Xtant Medical's state-of-the-art center for biologics processing in Belgrade, Montana.

When and where will Xtant Medical (XTNT) showcase OsteoVive Plus in 2024?

Xtant Medical will showcase OsteoVive Plus at the North American Spine Society (NASS) 2024 annual meeting, held from September 25-28, 2024 at McCormack Place in Chicago, booth #4402.